ArticleGut pathogens2026
Surfactin from Bacillus subtilis 1-4 disrupts the cell membrane of zoonotic Staphylococcus intermedius in vitro and maintains gut microbiota community in urban pigeons.
Article in Gut pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundUrban pigeons frequently carry zoonotic, antibiotic-resistant Staphylococcus spp. and are increasingly recognized as reservoirs of multidrug-resistant (MDR) gut pathogens with One Health implications. Probiotic Bacillus strains and their lipopeptide products, such as surfactin, are promising antibiotic-sparing alternatives, but their in vivo effects on host gut microbiota and pathogen carriage in apparently healthy birds remain poorly characterized.
resultsTo explore alternative antimicrobial strategies, Bacillus subtilis 1-4 was isolated from soil and shown to produce surfactin, a potent antimicrobial peptide. In vitro, surfactin exhibited bactericidal activity against S. aureus and S. intermedius by compromising membrane integrity. To evaluate its in vivo effects, pigeons (Columba livia) were treated with surfactin for seven days, and changes in their gut microbiota were characterized using full-length 16 S rRNA gene sequencing. While microbial α- and β-diversity remained largely unchanged, the surfactin-treated microbiota displayed enhanced compositional stability relative to controls.
conclusionsThese findings support surfactin's potential as a targeted antimicrobial agent with minimal disruption to the host gut microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.